Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
暂无分享,去创建一个
M. Kalos | Xiaohong Xu | S. Castaneda | I. Inigo | Kyla E. Driscoll | K. Benhadji | D. Surguladze | S. Guba | Yanxia Li | Gerald E. Hall | Mary Murphy | David A. Schaer | Yiwen Li | D. Nugent